MOR News and Press, MorphoSys AG From 11/08/23

2023-11-08 15:07:59 ET More on Xencor Xencor, Inc. (XNCR) Q3 2023 Earnings Call Transcript Xencor: Data In Early 2024 Could Bring Shareholder Value Xencor: A Mid-Stage Clinical Company With Falling Losses Xencor GAAP EPS of -$0.40 beats by $0.31, revenue of $...

Following topline results expected in the coming weeks, the oral session at ASH 2023 in December will provide detailed findings from MANIFEST-2 Investor event focused on MANIFEST-2 with MorphoSys management and medical experts will be hosted onsite on Monday, December 11 Additional ASH ...

2023-10-25 05:54:08 ET More on MorphoSys MorphoSys: Pelabresib Data Coming Out Soon, More Room To Run MorphoSys: Stable Liquidity Amid Challenging Markets Seeking Alpha’s Quant Rating on MorphoSys Historical earnings data for MorphoSys For furt...

Preliminary Q3 2023 Monjuvi U.S. net product sales of US$ 23.4 million (€ 21.5 million) Preliminary Gross Margin for Monjuvi U.S. net product sales for Q3 2023 of 65% Anticipate full year 2023 Monjuvi U.S. net product sales to be US$ 85-95 million and full year gross margin ...

Tulmimetostat follows pelabresib (2018) and tafasitamab (2014) as the company's third clinical program to receive Fast Track designation PLANEGG and MUNICH, GERMANY / ACCESSWIRE / September 12, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the U.S. Food and Drug Administrati...

2023-09-11 08:30:28 ET Crinetics Pharmaceuticals ( CRNX ) +66% climbs as lead asset succeeds in Phase 3 trial for acromegaly. Plus Therapeutics ( PSTV ) +25% Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Preventi...

2023-09-11 08:30:28 ET Crinetics Pharmaceuticals ( CRNX ) +66% climbs as lead asset succeeds in Phase 3 trial for acromegaly. Plus Therapeutics ( PSTV ) +25% Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Preventi...

2023-09-05 10:16:43 ET Summary MorphoSys' Q2 2023 earnings exceeded expectations, with Monjuvi sales reaching $23.6m and an operational loss improvement. The company has a solid cash reserve of approximately EUR680m, providing a cash runway for 1-2 years. The upcoming topline ...

2023-08-18 09:14:52 ET Summary MorphoSys reported a decrease in Q2 2023 total revenues to $58.0M and an operating loss of $55.0M. Cash and financial assets totaled approximately $733 million. Pelabresib, a BET inhibitor, shows promise as a treatment for myelofibrosis. In the MANIF...

2023-08-10 11:40:10 ET MorphoSys AG (MOR) Q2 2023 Earnings Conference Call August 10, 2023 8:00 AM ET Company Participants Julia Neugebauer – Head of Investor Relations Jean-Paul Kress – Chief Executive Officer Tim Demuth – Chief Research and...